| PICO | Description |
|---|---|
| Population | Adults diagnosed with type 2 diabetes mellitus (T2DM). |
| Intervention | Ebenatide treatment for 24 weeks. |
| Comparison | Standard care or placebo. |
| Outcome | Ebenatide significantly reduced HbA1c, improved time-in-range (TIR) and triglyceride-glucose index (TyG), and decreased body weight and waist-to-height ratio (WHtR) after 24 weeks. These benefits were sustained for at least 52 weeks, with mild gastrointestinal side effects reported. |
RCT
Front Endocrinol · 2025
Ebenatide in type 2 diabetes
RCT · type 2 diabetes · 24 weeks
Trial design
Between-group effect (95% CI)
HbA1c diff
-0.57%
vs placebo, p=0.011
Ebenatide HbA1c
8.5 to 7.3%
baseline to Wk 24
HbA1c <7%
37% vs 17%
target at Wk 24
TIR
43 to 82%
Ebenatide, Wk 24
⬡ Bottom Line
Over 24 weeks, Ebenatide cut HbA1c significantly more than placebo (between-group difference 0.57%) and roughly doubled the share of patients reaching HbA1c under 7%. Gains in time-in-range and body fat were sustained to 52 weeks, with only mild gastrointestinal effects.
P
Population
Adults with type 2 diabetes, HbA1c 7-11%
I
Intervention
Ebenatide 2 mg subcutaneously once weekly
C
Comparator
Placebo plus diet and exercise
O
Outcome
HbA1c change from baseline at Week 24